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Objective  To report the characteristics of myofascial trigger points (MTrPs) in the infraspinatus muscle and 
evaluate the therapeutic effect of trigger-point injections.
Methods  Medical records of 297 patients (221 women; age, 53.9±11.3 years) with MTrPs in the infraspinatus 
muscle were reviewed retrospectively. Because there were 83 patients with MTrPs in both infraspinatus muscles, 
the characteristics of total 380 infraspinatus muscles with MTrPs (214 one side, 83 both sides) were investigated. 
Specific characteristics collected included chief complaint area, referred pain pattern, the number of local twitch 
responses, and distribution of MTrPs in the muscle. For statistical analysis, the paired t-test was used to compare a 
visual analogue scale (VAS) before and 2 weeks after the first injection.
Results  The most common chief complaint area of MTrPs in the infraspinatus muscle was the scapular area. The 
most common pattern of referred pain was the anterolateral aspect of the arm (above the elbow). Active MTrPs 
were multiple rather than single in the infraspinatus muscle. MTrPs were frequently in the center of the muscle. 
Trigger-point injection of the infraspinatus muscle significantly decreased the pain intensity. Mean VAS score 
decreased significantly after the first injection compared to the baseline (7.11 vs. 3.74; p<0.001).
Conclusion  Characteristics of MTrPs and the therapeutic effects of trigger-point injections of the infraspinatus 
muscle were assessed. These findings could provide clinicians with useful information in diagnosing and treating 
myofascial pain syndrome of the infraspinatus muscle.
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INTRODUCTION
Nonspecific complaints of pain near the scapula are 
commonly encountered, and may originate from any dis-
order of the cervical spine or shoulder joint. In some cas-
es, however, pain near the scapula appears without any 
relation to the cervical spine or shoulder, and additional 
clinical studies are required to reveal possible causes of 
pain and to find the effective treatments.
Myofascial trigger points (MTrPs) may offer an alterna-
tive explanation for the pathophysiological mechanism 
of scapular pain. Although MTrPs are rarely a primary 
origin of pain [1,2], evidence suggests that MTrPs are 
caused by or related to a lesion in another soft tissue, 
such as spine disorder or rotator cuff disease [2,3]. MTrPs 
are local points that are highly sensitive to pressure. 
Their palpation causes characteristic referred sensations, 
including pain, muscle dysfunction, and sympathetic 
hyperactivity [4-6]. MTrPs are classified into active and 
latent. Active MTrPs present clinical pain with or without 
activity associated with tenderness in a taut band, where-
as latent MTrPs are clinically quiescent and are painful 
only when palpated.
Based on our clinical experiences, many patients with 
or without spine or rotator cuff diseases also have scapu-
lar pains that originate in the infraspinatus muscle. The 
infraspinatus muscle, a thick and triangular muscle, oc-
cupies the chief part of the infraspinatus fossa and assists 
external rotation of the arm and stabilization of the hu-
merus head during an arm movement [7]. Active MTrPs 
in this muscle cause both local pain and referred pain in 
the shoulder region and down to the frontal and lateral 
side of the arm [5].
The infraspinatus muscle frequently harbors MTrPs. In 
one study with 126 patients, referred pain to the shoulder 
region arose from the infraspinatus muscle in 31% of the 
cases, a frequency second only to that of the levator scap-
ulae (55%) [8]. Another study reported similar results [9]. 
Among young, pain-free adults, the infraspinatus muscle 
was the third (18%) in the prevalence of latent MTrPs, 
following the levator scapulae (20%) and the upper trape-
zius (35%) [10].
We recently observed many patients who were com-
patible with the criteria of MTrPs in the infraspinatus 
muscle, as assessed by careful history taking and physical 
examination. In treating these patients, we found some 
differences from previous studies [11] in the chief com-
plaint area, referred pain pattern, distribution of MTrPs, 
and therapeutic effect of trigger-point injection.
The objectives of this study were to report on the char-
acteristics of MTrPs in the infraspinatus muscle.
MATERIALS AND METHODS
Participants
After Institutional Review Board approval, we retro-
spectively reviewed the medical records of 446 patients 
with suspected MTrPs in the infraspinatus muscle who 
had visited the outpatient clinic of Severance Hospital 
between March 2013 and November 2015 in order to 
identify all eligible patients (4-2015-1049).
Diagnosis of active MTrPs was based on prior criteria, 
including tender spots in the infraspinatus muscle, a 
compatible pattern of referred pain elicited when tender 
spots were compressed, restricted range of motion of the 
shoulder, and palpable or visible local twitch responses 
(LTRs) at the most sensitive spot in the taut band. LTRs 
were elicited and assessed during trigger-point injec-
tions. Since needling is more sensitive than manual 
palpation in identifying LTRs, the needling method was 
chosen to confirm the presence of MTrPs.
Among patients with MTrPs in the infraspinatus mus-
cle, those who met the following criteria were included in 
this study: MTrPs of muscle and fascia, exclusive of en-
thesopathy; pain score measured by a visual analog scale 
(VAS) greater than 2 (≥3) on a numeric scale of 0−10; and 
having a trigger-point injection. Patients were excluded 
if they had: (1) received treatment that could affect the 
result (such as pain killers, physical therapy, or other 
injection therapy) from 2 weeks before intervention and 
through the follow-up period; (2) some other systemic 
disease that could present the same symptom (e.g., fi-
bromyalgia); (3) neurologic shoulder/scapular pain (e.g., 
cervical radiculopathy or peripheral nerve injury); and (4) 
previous history of an adverse effect of lidocaine or ste-
roid, or any conditions or situations that might place the 
patient at significant risk during the injection. 
However, if the patient met the criteria of MTrPs in the 
infraspinatus muscle, they were not excluded even if they 
had a history of the rotator cuff and/or cervical spine dis-
ease.
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Trigger-point injection 
All injections were performed under ultrasound (US)-
guided injection. However, this retrospective design of 
the study was not to evaluate the usefulness of US-guided 
injection of the infraspinatus. The US-guided trigger-
point injection method previously reported for the lower 
back muscles, deep pelvic muscles, and the brachialis 
muscles was modified for MTrPs in the infraspinatus 
muscles [12-14]. We performed B-mode, real-time US in 
a sterile environment using an Accuvix V10 US machine 
A B
Fig. 1. Proper position during the injection procedure. (A) The patient is positioned prone with the affected arm ex-
tended, internally rotated, and adducted. The patient then tries to reach the thoracic spine. In this position, the border 
of scapular bone moves away from other surrounding tissues and the border of the infraspinatus muscle is easily ob-
served. (B) The probe is positioned on the most tender point to show the transverse image of the infraspinatus muscle, 
and an out-of-plane approach is used for the needle.
D
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Fig. 2. Ultrasound images of the 
infraspinatus muscle. The ul-
trasound transducer was placed 
separately in the images shown 
in panels (A), (B), and (C). Trans-
verse scan shows the infraspi-
natus, deltoid, and teres minor 
muscles. Isp, infraspinatus; Tm, 
teres minor; D, deltoid.
Junbeom Kwon, et al.
576 www.e-arm.org
(Medison, Seoul, Korea) interfaced with a 5- to 12-MHz 
linear array transducer around the target muscle. A phys-
iatrist with more than 8 years of experience in the mus-
culoskeletal US carried out all the US-guided injection 
procedures. 
The patients lay prone on an examination bed with the 
affected arm extended, internally rotated, and adducted, 
and try to reach the thoracic spine—that is, in a position 
similar to the surgical “chicken wing” position for injec-
tion procedures (Fig. 1). With this position, we could eas-
ily and safely approach the infraspinatus muscle by sepa-
rating the scapular bone from the surrounding tissues.
We differentiated the infraspinatus muscle from the 
deltoid, trapezius, teres major, teres minor, and latis-
simus dorsi muscles by US scanning and marked the 
tender points on the skin by palpating the muscle. By 
positioning the probe on the marked points and turn-
ing the probe for the best view, we obtained the image 
of the target area (Figs. 1, 2). Color Doppler images were 
used to avoid the neurovascular bundle. Under US guid-
ance, a 25-gauge, 2.6-cm needle connected to a 5-mL 
syringe containing a mixture of 4 mL of 0.5% lidocaine 
and 1 mL of 40 mg of triamcinolone was inserted into the 
infraspinatus muscle at the region where the tender spot 
was palpated. In the case of multiple tender spots in one 
muscle, the injections were repeated for all tender spots. 
The sequence of the injection sites was determined at 
each treatment period in terms of the decreasing order 
of pain severity in the tender points when palpated. The 
injection volume per tender point was 0.5 mL. No more 
injections were done once all the prepared solution of 5 
mL had been used up (at most, there could be 10 injec-
tions per treatment session) or when no more palpated 
tender point were found. With the use of an out-of-plane 
method, we could see the needle passing through the 
skin and adipose tissue to penetrate the muscle. The 
physiatrist observed the LTRs on the US while performing 
the trigger-point injections. The needling was repeated 
to elicit as many LTRs as possible. If no LTR was observed 
after 10 attempts, the needling was stopped and a mix-
ture solution was injected. The injection site was pressed 
to ensure proper hemostasis after the procedure. Trigger-
point injections were carried out in all MTrPs of the mus-
cle at 2-week intervals. Additional injections were not 
considered if patients were satisfied with the reduction 
in discomfort or pain severity, or if patients did not want 
another injection for some reason. The patients were 
taught to do stretching exercise (repeated 10−20 times 
daily) and to avoid any posture that might aggravate the 
symptoms.
Data collection 
Demographic and clinical data including age, gender, 
affected side, and the duration of symptoms were collect-
ed. Pain intensity, duration of symptoms, chief complaint 
area, referred pain pattern, the number of injections, and 
the number of LTRs were recorded, and the distribution 
of MTrPs in the muscle was established in terms of the 
sites of LTRs that were given US-guided injections (Fig. 3). 
Pain intensity was measured by using a 10-cm horizontal 
VAS, which ranged from 0 (no pain) to 10 (worst imagin-
able pain). VAS was assessed at baseline and at 2 weeks 
after each injection. 
Statistical analyses
We carried out descriptive analyses of patient informa-
43 (2.9) 191 (13.0) 164 (11.2) 99 (6.7)
78 (5.3) 288 (19.6) 248 (16.9)
39 (2.7) 214 (14.6)
104 (7.1)
n (%)
Fig. 3. Distribution of myofascial trigger points (MTrPs). 
MTrPs measurement sites (circles) and needling sites (at 
the center of each circle). The triangular infraspinatus 
muscle is divided into 10 subareas on each side of the 
shoulder. Values are presented as numbers of MTrPs on 
the painful side (%).
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tion and characteristics of MTrPs in the infraspinatus 
muscle. For patients with MTrPs in both infraspinatus 
muscles, pain intensity, duration of symptoms, chief 
complaint area, referred pain pattern, the number of 
injections, and the number of LTRs were evaluated on 
each side. Evaluation of the effect of the trigger-point 
injections used the Shapiro-Wilk test of the VAS data ac-
quired at baseline and at 2 weeks after the first injection 
to find out whether the distribution was normal. When 
the Shapiro-Wilk test showed a normal distribution for 
these parameters, a paired t-test was used to compare 
parameters before and 2 weeks after the first injection. 
Statistical significance was set at a p-value of <0.05. SPSS 
ver. 21.0 software (IBM, Armonk, NY, USA) was used for 
all statistical analyses.
RESULTS
We reviewed the medical records of 446 patients with 
suspected MTrPs in the infraspinatus muscles between 
March 2013 and November 2015. Of these, 297 patients 
(221 females and 76 males) were eligible for this study. 
Because there were 83 patients with MTrPs in both infra-
spinatus muscles, there were 380 cases of infraspinatus 
muscles with MTrPs that satisfied the inclusion criteria. 
In 83 patients with MTrPs in both infraspinatus muscles, 
both muscles were evaluated separately for the duration, 
pain severity, chief complaint area, and pattern of re-
ferred pain. The demographic and clinical characteristics 
of 297 patients and the clinical characteristics of the 380 
infraspinatus muscles with MTrPs are summarized in 
Table 1.
Among the 297 patients, there were 103 with a medical 
history of shoulder disease, including rotator cuff disease 
(n=103, 34.7%), sports or work-related injury without 
shoulder and cervical spine disease (n=89, 30.3%). cer-
vical spine disease (n=61, 20.5%), and shoulder disease 
combined with cervical spine disease (n=44, 14.8%). 
Among the patients with work-related injury, we found 
that 17 (5.7%) took care of the children.
In the 380 infraspinatus muscles with MTrPs, the most 
common chief complaint area was the scapular area; the 
next most common was deep in the front of the shoulder 
(Table 1). One hundred thirty-one cases had referred 
pain except in the areas of chief complaint; the most 
common area was the anterolateral aspect of the arm 
(above the elbow) (Table 2).
The LTRs necessary for diagnosing MTrPs were identi-
fied in all 380 infraspinatus muscles. However, the num-
ber of LTRs was recorded in the medical charts for only 
153 cases. Of these, 38 cases (24.8%) had fewer than 5 
LTRs. Cases with 6–10, 11–15, 16–20, and >10 LTRs were 
45 (29.4%), 46 (30.1%), 24 (15.7%), and 70 (45.8%), re-
Table 1. Demographic and clinical characteristics of in-
fraspinatus muscles with MTrPs
Characteristic Value
Age (yr) 53.9±11.3 
(44.0–56.8)
Gender (n=297)
   Female 221 (74.4)
Affected side (n=297)
   Right 100 (33.7)
   Left 114 (38.4)
   Bilateral 83 (27.9)
Duration of symptoms 19.4±22.5
VAS at baseline 6.7±2.0
Chief complaint area (n=380)
   Scapular area (including the back of 
     shoulder, interscapular area)
197 (51.8)
   Deep in the front of the shoulder 
     (including anterior deltoid area)
128 (33.7)
   Deep within the shoulder joint 29 (7.6)
   Base of the neck 21 (5.5)
   Others 5 (1.3)
Values are presented as mean±standard deviation (range) 
or number (%).
MTrPs, myofascial trigger points; VAS, visual analogue 
scale.
Table 2. Pattern of referred pain of infraspinatus muscles 
with MTrPs
Pattern of referred pain
No. of  
patients (%)
To the anterolateral aspect of the arm 
  (above the elbow)
72 (55.0)
To the lateral forearm 20 (15.3)
To upper posterior neck 19 (14.5)
To the radial aspect of the hand 
  (including fingers)
18 (13.7)
Others 2 (1.5)
Total 131 (100)
MTrPs, myofascial trigger points.
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spectively.
Fig. 3 summarizes the distribution of MTrPs in the in-
fraspinatus muscles based on the scapular bone in 297 
patients. For all 380 cases, 1,468 MTrPs were found, aver-
aging 4.9 MTrPs per muscle. 
Among the 380 cases, the effect of the trigger-point in-
jections was assessed for 135 cases. One injection was 
given to 16 (11.9%) of the 135 patients, 2 injections at an 
interval of 2 weeks for 88 patients (65.2%), and 3 injec-
tions every 2 weeks for 31 patients (23.0%). There was a 
significant decrease in the VAS at 2 weeks after the first 
injection compared to the baseline (p<0.001). The mean 
value decreased significantly from 7.11 (SD=1.45) pre-
treatment to 3.74 (SD=1.53) after the first treatment.
DISCUSSION
There are three important findings in this study. First, 
one of the main symptoms of MTrPs in the infraspina-
tus muscle is scapular pain. Second, active MTrPs were 
almost always multiple rather than single in the infra-
spinatus muscle on the painful side. Third, inactivation 
of active MTrPs in the infraspinatus muscle significantly 
decreased pain intensity.
The main symptom of MTrPs in the infraspinatus mus-
cle was pain deep in the front of the shoulder, including 
the anterior deltoid area, in previous studies [9,15-18]. 
Although the pain from MTrPs was frequent deep in the 
front of the shoulder, pain in the scapular area was more 
common in this study. These findings may depend on 
the differences in the definition of the MTrPs, the patient 
population, and the exactitude of the questions asked to 
patients during the medical examination. 
First, MTrPs can exist within skeletal muscle tissue, 
aponeurosis (fascia) of the muscle, or the tendon, but 
this study was restricted to MTrPs within the infraspi-
natus muscle tissue and/or fascia of the muscle, which 
is the most common type of MTrPs [19]. Second, we did 
not exclude patients who had a history of cervical spine 
disease or shoulder lesion if the patients met the criteria 
of MTrPs in the infraspinatus muscle. Third, because pa-
tients may not be able to distinguish scapular pain from 
shoulder pain, the physiatrist asked questions to find out 
if the pain presented exactly around the scapular area 
during the medical examination. If the physiatrist did not 
ask specifically about scapular pain, a patient could have 
thought the question was about shoulder pain.
Referred pain is a pain felt in other than the true site of 
origin [20]. In this study, the locations of referred pain 
from MTrPs in the infraspinatus muscle were, in order of 
frequency, the anterolateral aspect of the arm (above the 
elbow), the lateral forearm, the upper posterior neck, and 
the radial aspect of the hand (including a finger). Our 
results were similar to those of a study of 193 patients, 
in which the anterolateral aspect of the arm (46%) was 
the most frequent site of the referred pain, followed by 
the lateral forearm (21%), the posterior neck (14%), and 
the radial aspect of the hand (13%) [9,11,15,16,18,21,22]. 
When the referred pain is on the radial aspect of the 
hand, it was especially important to differentiate it from 
cervical radiculopathy, mainly at the C5 or C6 level [23]. 
The range and site of the referred pain can depend on 
the location and intensity of the MTrPs in the infraspi-
natus muscle, and further study is required. MTrPs in 
the infraspinatus and teres minor muscles often occur 
together and are often incorrectly assessed as rotator cuff 
lesions or cervical discogenic pain. In addition, MTrPs in 
the infraspinatus muscle are often incorrectly assessed 
as osteoarthritis of the shoulder joint, entrapment of the 
suprascapular nerve, or bicipital tendinitis [19]. Also, 
MTrPs in the infraspinatus muscle should be differentiat-
ed from those in the teres major, supraspinatus, anterior 
deltoid, subscapularis, and pectoralis major muscles [19].
One of the main contributions of our study is the find-
ing that there were multiple, not just single, active MTrPs 
in the infraspinatus muscle on the painful side. Further-
more, there are many LTRs per infraspinatus muscle, and 
cases of more than 10 LTRs were frequently observed 
(45.8%). If LTRs are elicited during injection, especially if 
the fast-in–fast-out technique was used, immediate pain 
relief could be achieved more often [24,25]. Patients can 
fail to experience immediate and complete pain relief if 
the LTRs are not elicited during a trigger-point injection. 
After injection into one responsive locus, other LTRs can 
be elicited. These procedures should be repeated until 
all (or as many as possible) responsive loci are injected 
[26]. To our knowledge, the number of LTRs has not been 
reported previously. Therefore, these results highlight 
the importance of searching for multiple active MTrPs 
regions and LTRs within one muscle in patients with 
myofascial pain syndrome in the infraspinatus muscle. 
Multiple MTrPs in the same muscle can each contribute 
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to the overall referred pain pattern.
Trigger-point injection of the infraspinatus muscle re-
sulted in excellent outcomes, and VAS scores decreased 
after treatment. We suggest that, in a patient with MTrPs 
in the infraspinatus muscle, trigger-point injection of the 
infraspinatus is effective for both diagnosis and treatment 
when the scapular pain is suspected to originate from the 
infraspinatus muscle. 
MTrPs in the infraspinatus are usually activated by 
an acute stress or by multiple overload stresses. These 
MTrPs may become active and induce pain under the 
influence of certain perpetuating factors, such as repeti-
tive and sustained shoulder activities [27,28]. This could 
be the explanation for the 17 patients without shoulder 
lesion who took care of children. When the shoulder is 
abducted and flexed, the infraspinatus muscle shows less 
activity than the supraspinatus muscle [29]. However, 
there is a marked increase of infraspinatus activity at over 
140o of abduction. Therefore, when the patient carries 
heavy loads for a long time with the shoulder abducted 
above the acromion level, the infraspinatus muscle could 
be damaged. These mechanisms could explain the cases 
of MPS in women without underlying disease who were 
actively involved in child care. Since the infraspinatus 
muscle, unlike the supraspinatus muscle, is likely to be 
strongly activated in movements that are unusual and 
transient, acute overload could be much more likely to 
develop MTrPs than tasks that impose a sustained over-
load [11].
The muscle imbalance may also keep the MTrPs ac-
tive and induce recurrent pain. Since MTrPs can induce 
changes in normal muscle-activation patterns and sub-
sequent motor dysfunction, identifying and inactivating 
MTrPs should improve motor function, release muscle 
stiffness, and restore normal biomechanics of the shoul-
der [30].
It is important to know the common sites of MTrPs in 
the infraspinatus muscle in order to provide guidance on 
the clinical identification of MTrPs in this muscle. Care-
ful palpation frequently discloses multiple tender spots 
in the infraspinatus muscle as indicated by the multiple 
lesions. In previous studies, the most common MTrPs 
region was caudal to the junction of the most medial and 
adjacent quarter of the length of the scapular spine (upper 
medial lesion) [11]. The next most common MTrPs region 
was caudal to the midpoint of the scapular spine (lateral 
upper lesion) [11]. In this study, the common MTrPs re-
gion was similar to that found by Travell, but was more 
broadly positioned, and the inferior angle of the scapula 
was more frequently observed. Because the infraspina-
tus muscle is quite broad and palpating all of it during 
the physical examination could be time-consuming, this 
study could provide a helpful guideline for identifying 
MTrPs in the infraspinatus muscle.
US-guided injection is useful for detecting LTRs in 
deeply located muscles and for controlling the depth 
during injection for even less-accessible muscles. US 
guidance can also reduce inadvertent injuries that could 
be caused by improper needle placement. It might seem 
unnecessary to use US-guided injection, because the 
infraspinatus muscle is located superficially, and the 
needle is less likely to injure surrounding tissues, such 
as the lung, inadvertently. However, by using US-guided 
injection, we could observe more LTRs to improve the ef-
fects of injection, differentiate the neighboring teres ma-
jor, deltoid, and trapezius muscles in order to diagnose 
more accurately, and provide feedback for the treatment 
by recording with built-in video. These strengths could 
be worthy of attention. 
There are some limitations to be considered in our 
study. First, because the study was retrospective, we 
could have missed information required for accurate 
analysis. 
Second, we conclude the therapeutic effects of trigger-
point injections without comparison to a control group. 
Nevertheless, we could not ignore the significant de-
crease in the VAS scale (more than 3 points) from injec-
tions during short-term treatment. 
Third, we investigated only one referred pain pattern 
per case. If multiple tender points exist, there could be 
many different referred pain patterns depending on the 
location, number, and pain severity of the tender points. 
This is also a limitation of a retrospective study, which 
could be complemented by further prospective studies. 
Fourth, the follow-up period of the therapeutic effect of 
the trigger-point injections was relatively short. Although 
there was no long-term follow-up, the long-term effects 
of trigger-point injections for MPS in the infraspinatus 
muscle would not differ from those for other muscles. If 
the underlying etiologic lesion cannot be eliminated, the 
effect of one trigger-point injection usually lasts about 
2 weeks [13]. Inactivation of active MTrPs, however, is 
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necessary for some situations, including the presence 
of severe and intolerable pain, pain or discomfort that 
interferes with functional activities, and persistent pain 
and tightness. The same principle can be applied to the 
infraspinatus muscle. 
Fifth, the selected group of patients was not homo-
geneous. In particular, some patients with shoulder or 
cervical spine lesions were included in this study. MTrPs 
could be secondary to pathologic conditions such as 
chronic repetitive minor muscle strain, poor posture, 
systemic diseases, and musculoskeletal lesions (such as 
strain, sprain, enthesopathy, bursitis, arthritis, and spi-
nal disc lesion) [2,3]. But for the patients with a history 
of shoulder or cervical spine lesion in our study, their 
lesions were not their main reason for visiting a clinic. In 
addition, their symptoms satisfied MTrPs criteria and, 
ironically, their MTrPs were less frequent than for pa-
tients without a history of shoulder or cervical spine le-
sion [1].
In conclusion, our findings of MTrPs in the infraspina-
tus muscle and the therapeutic effect of trigger-point in-
jections in that muscle may provide clinicians with useful 
information in diagnosing and treating myofascial pain 
syndrome of the infraspinatus muscle.
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